Skip to main content
Caplight Logo









Neuroplast

Neuroplast

Private
MaastrichtHealthcare & Life Scienceshttps://www.neuroplast.com/

Last Round

Series B

Nov 17, 2021

Total Funding Raised

$15.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neuroplast is a biotechnology company that develops the autologous stem cell platform product Neuro-Cells®, a treatment to combat neurodegeneration resulting from trauma, disease and ageing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

autologous stem cell therapyregenerative medicinespinal cord injurystem cell researchcell therapybiotechnologyneurodegenerative diseaseclinical trialsbone marrow-derived cellstissue repairpersonalized medicinebiologicsGMP manufacturingATMPadvanced therapy medicinal products

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neuroplast Comparables

Compare Neuroplast with similar companies based on industry and business-model similarity.

Neuroplast comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regeneration Biomedical, Inc.
79%
Matricelf Ltd
77%
Brainstorm Cell Therapeutics Inc.
77%

Neuroplast Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 17, 2021
Series AFeb 19, 2020

Key People

Founding team and executive leadership

Frans van den Berg

CEO

Executive Team

Neuroplast Investors

Notable investors and investment history

Neuroplast investors
InvestorRounds
819 Capital PartnersSeries A
Brightlands Venture PartnersSeries B, Series A
Lumana InvestSeries B
LIOFSeries B, Series A
Netherlands Enterprise AgencySeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 17, 2026

    Grew 33% QoQ from 9 to 12 employees.

  • Apr 25, 2026

    Grew 43% QoQ from 7 to 10 employees.

Neuroplast Filings

Explore SEC and related filing metadata, where available.

Neuroplast filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neuroplast's valuation, stock price, and market status.

Is Neuroplast a public or private company?

Neuroplast is a private company.

What is the current stock price of Neuroplast?

Neuroplast is a private company with no public stock price. No recent secondary market data is available.

How much is Neuroplast worth (valuation)?

Valuation information for Neuroplast is not publicly available.

Can I buy Neuroplast stock?

Neuroplast shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neuroplast's last funding round?

Neuroplast's most recent funding round was Series B on November 17, 2021.

Who are the main investors in Neuroplast?

Key investors in Neuroplast include Lumana Invest.

Will Neuroplast IPO soon?

No public IPO plans have been announced for Neuroplast.

How can I track Neuroplast secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neuroplast's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMaastricht
Employee Range12
Year Founded2014
Last FundingNov 17, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?